Atit Mishra

Atit Mishra

Active Director Director DIN 07771606
DIN 07771606 First appointment Apr 2017 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2017
Shareholding value •••• Premium profile

About Atit Mishra

Data last updated:

Atit Mishra is a Director at Medigenesis Pharma Private Limited (since 2017). The company operates in Healthcare. Medigenesis Pharma Private Limited reported revenue of ₹1.02 Cr (FY 2024).

DIN 07771606
Primary Designation Director
Industry Healthcare
First Appointment 04 Apr 2017
Oldest Company Age 9 yrs
Largest company Medigenesis Pharma Private Limited · ₹1.02 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Medigenesis Pharma Private Limited U74999DL2016PTC309240
Director04 Apr 20172016₹1.02 Cr (FY 2024)Active

Board colleagues of Atit Mishra

Directorship timeline

Open interactive timeline →
Medigenesis Pharma Private Limited
Premium access

Shareholding and investment profile for Atit Mishra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Atit Mishra

Atit Mishra currently holds 1 directorship: Medigenesis Pharma Private Limited (Director, since 04 Apr 2017, revenue ₹1.02 Cr (FY 2024)).

Atit Mishra was first appointed on 04 Apr 2017 as Director at Medigenesis Pharma Private Limited.

The current boards of Atit Mishra's companies include Banti Singh (Medigenesis Pharma Private Limited), Vishal Maheshwari (Medigenesis Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available